uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
In vivo Drug Delivery Performance of Lipiodol-based Emulsion or Drug-eluting Beads in Patients with Hepatocellular Carcinoma
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy.
Show others and affiliations
2016 (English)In: Molecular Pharmaceutics, ISSN 1543-8384, E-ISSN 1543-8392Article in journal (Refereed) Epub ahead of print
Abstract [en]

Doxorubicin (DOX) delivered in a lipiodol-based emulsion (LIPDOX) or in drug-eluting beads (DEBDOX) is used as palliative treatment in patients with intermediate-stage hepatocellular carcinoma (HCC). The primary objective of this study was to evaluate the in vivo delivery performance of DOX from LIPDOX or DEBDOX in HCC patients using the local and systemic pharmacokinetics of DOX and its main metabolite doxorubicinol (DOXol). Urinary excretion of DOX and DOXol, and their short-term safety and anti-tumor effects were also evaluated. In this open, prospective, non-randomized multi-center study, LIPDOX (n=13) or DEBDOX (n=12) were injected into the feeding arteries of the tumor. Local (vena cava/hepatic vein orifice) and systemic (peripheral vein) plasma concentrations of DOX and DOXol were determined in samples obtained up to 6 h and 7 days after treatment. Tumor response was assessed using computed tomography or magnetic resonance imaging. The Cmax and AUC0-24 h for DOX were 5.6-fold and 2.4-fold higher in LIPDOX vs DEBDOX recipients, respectively (p <0.001). After 6 h, the respective mean proportions of the dose remaining in the liver or drug-delivery system (DDS) were 49% for LIPDOX and 88% for DEBDOX. LIPDOX releases DOX faster than DEBDOX in HCC patients and provides more extensive local and systemic exposure (AUC) to DOX and DOXol initially (0-7 days). DEBDOX formulation has a release and distribution of DOX that is more restricted and rate controlled than LIPDOX.

Place, publisher, year, edition, pages
2016.
National Category
Social and Clinical Pharmacy
Identifiers
URN: urn:nbn:se:uu:diva-311314DOI: 10.1021/acs.molpharmaceut.6b00886PubMedID: 27997198OAI: oai:DiVA.org:uu-311314DiVA: diva2:1059622
Available from: 2016-12-22 Created: 2016-12-22 Last updated: 2017-01-20Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Lilienberg, ElsaDubbelboer, Ilse REbeling Barbier, CharlotteNorén, AgnetaDuraj, FransSjögren, ErikNyman, RickardLennernäs, Hans
By organisation
Department of PharmacyRadiologyUpper Abdominal Surgery
In the same journal
Molecular Pharmaceutics
Social and Clinical Pharmacy

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 25 hits
ReferencesLink to record
Permanent link

Direct link